http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2015104886-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-63 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2015-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2015104886-A |
| titleOfInvention | 9-Oxo-9H-fluorene hepatitis B virus replication inhibitors and pharmaceutical composition for the treatment of hepatitis B |
| abstract | 1. Hepatitis B virus replication inhibitors, which are 9-oxo-9H-fluorene-2,7-disulfonic acids bis-arylamides of the general formula 1, their pharmaceutically acceptable salts and / or hydrates where Ar and Ar are phenyl, optionally substituted with one, two or three the same or different substituents selected from C-C1-6alkyl, methoxyl, halogen, carboxyl and carbamoyl, optionally substituted with the same or different substituents, where the substituents are selected from C-C1-6alkyl, diC-C1-6alkylamino-C1-6alkyl, C-C1-6alkylamino-C1-6alkyl or where Titel together with the nitrogen atom to which they are attached may form a 6-membered heterocyclyl containing further heteroatom selected from nitrogen and optionally substituted C Salkilom.2. The inhibitors according to claim 1, which are 9-oxo-9H-fluorene-2,7-disulfonic acids bis-arylamide selected from a number of compounds of the formula 1.1-1.123. A pharmaceutical composition in the form of tablets, capsules or injections in a pharmaceutically acceptable package for the treatment of hepatitis B, comprising a hepatitis B virus replication inhibitor of general formula 1 according to claim 1, a pharmaceutically acceptable salt and / or hydrate thereof in a therapeutically effective amount. A method for preparing a pharmaceutical composition by mixing with an inert excipient and / or solvent of at least one inhibitor of the general formula 1 according to claim 1 or a pharmaceutically acceptable salt and / or hydrate thereof in a therapeutically effective amount. A method for the prevention and treatment of hepatitis B virus, which comprises administering to the patient a hepatitis B virus replication inhibitor of general formula 1 according to claim 1, a pharmaceutically acceptable salt and / or hydrate thereof, or a pharmaceutical composition according to claim 3, |
| priorityDate | 2015-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.